Evaluation of Checkpoint Inhibitors in Cancer Patients With End-stage Renal Disease on Hemodialysis: Case Series and Review of the Literature. Issue 8 (October 2020)

• Record Type: Journal Article
• Authors: Jain, Jayanshu; Stein, Jill; Garje, Rohan
• Is Part Of: Journal of immunotherapy. Volume 43:Issue 8(2020:Oct.)
• Publication Date: 2020-10
• Subjects: checkpoint inhibitors -- immunotherapy -- end-stage renal disease -- dialysis; Immunotherapy -- Periodicals; Immunotherapy -- Periodicals; Neoplasms -- therapy -- Periodicals; Electronic journals; Electronic journals; 615.37
• DOI: 10.1097/CJI.0000000000000327
• Languages: English
• ISSNs: 1524-9557

Abstract

Abstract : Checkpoint inhibitors (CPIs) have become standard of care for multiple types of malignancies and while end-stage renal disease is not a contraindication, these patients are frequently excluded from clinical trials. As a result, there is limited data regarding the safety and efficacy of CPI use in this patient population. In this case series, we report outcomes and adverse events in 8 patients on hemodialysis treated with CPIs. Treatment was overall well-tolerated with adverse events in 3 of 8 (37.5%) patients, with 1 (12.5%) having a grade 4 adverse event, which is comparable to the rate reported in literature for the overall population receiving CPI. No treatment related deaths were seen. Because of small sample size, efficacy data is limited. Further studies are needed in this patient population to elucidate the true incidence of adverse events and antitumor activity.